Study of High-dose Spironolactone vs. Placebo Therapy in Acute Heart Failure
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 360 participants.
Also called NCT02235077
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 360 participants
- Registry
-
NCT02235077
-
- Other papers using this trial's data
- Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial
- Spironolactone in Acute Heart Failure Patients With Renal Dysfunction and Risk Factors for Diuretic Resistance: From the ATHENA-HF Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT02235077. Randomized; triple masking; primary purpose treatment. Start 2014-12-30 (actual); primary completion 2016-04-12 (actual). Results posted on 2017-05-17.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study of High-dose Spironolactone vs. Placebo Therapy in Acute Heart Failure
- Acronym
- ATHENA-HF
- Condition
- Heart Failure
- Intervention (Drug)
- Spironolactone
- Intervention (Drug)
- Placebo
- Lead sponsor
- Duke University
- Collaborator
- National Heart, Lung, and Blood Institute (NHLBI)
Record details
- Record id
cardio:ct-nct02235077- Content hash
f861ba58e7a947ae43eb41ea4aee91737e2d4f050ad1e076d70d7a36b58f9382